Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Gynecologic Cancer 1

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Surveys and Questionnaires 6Cisplatin 6Brachytherapy 5Doxorubicin 4Docetaxel 4Pemetrexed 3Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3FANG vaccine 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × fosaprepitant × Gynecologic × Clear all
NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡